©The Author(s) 2015.
World J Gastroenterol. May 14, 2015; 21(18): 5445-5453
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5445
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5445
Table 3 Current status of MET inhibitors for the treatment of advanced hepatocellular carcinoma
| First-line therapy of advanced HCC |
| INC280: A phase II sing-arm trial (NCT01737827) |
| MSC2156119J vs sorafenib: A phase II RCT (NCT01988493) |
| Golvatinib plus sorafenib vs sorafenib alone: A phase II RCT (NCT01271504) |
| Foretinib: A phase II sing-arm trial (NCT00920192) |
| Second-line therapy of advanced HCC |
| Tivantinib vs placebo: A phase II RCT (NCT00988741) |
| Tivantinib vs placebo: A phase III RCT (NCT01755767) |
| Cabozantinib vs placebo: A phase II randomized discontinuation trial (NCT00940225) |
| Cabozantinib vs placebo: A phase III RCT (NCT01908426) |
| INC280 vs placebo: A phase II RCT (NCT01964235) |
| MSC2156119J: A phase II sing-arm trial (NCT02115373) |
- Citation: Qi XS, Guo XZ, Han GH, Li HY, Chen J. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol 2015; 21(18): 5445-5453
- URL: https://www.wjgnet.com/1007-9327/full/v21/i18/5445.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i18.5445